Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease - Wikidata - awgldk - TriplyDB

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease

http://www.wikidata.org/entity/Q35611709

about

Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer.Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach.Multivariate classification of urine metabolome profiles for breast cancer diagnosis ProteoMiner™ and SELDI-TOF-MS: a robust and highly reproducible combination for biomarker discovery from whole blood serum.A metaproteomic approach to study human-microbial ecosystems at the mucosal luminal interface.Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia.Myelodysplastic syndromes: diagnosis, prognosis, and treatment.Identification of serum CCL15 in hepatocellular carcinoma.Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion.An empirical assessment of validation practices for molecular classifiers Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome Going from genes to proteins in myelodysplastic syndromes.Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups.MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment.Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome.Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling.Update on genetic and molecular markers associated with myelodysplastic syndromes.Mass spectrometry-based proteomics and its potential use in haematological research.The proteomic analysis of human neonatal umbilical cord serum by mass spectrometry.Prognostic molecular markers in myelodysplastic syndromes.The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.Serum proteomics in biomedical research: a systematic review.CXCL4 Exposure Potentiates TLR-Driven Polarization of Human Monocyte-Derived Dendritic Cells and Increases Stimulation of T Cells.Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia.Platelets: much more than bricks in a breached wall.Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.Comparative proteomics in acute myeloid leukemia.Partial reprogramming of heterologous cells by defined factors to generate megakaryocyte lineage-restricted biomolecules

P2860

Q30987570-A07015CC-D90C-414C-8659-2479FF0E1AA9 Q33310515-DFFF2C15-7EE2-43CC-89F8-6AB2CE45D0BA Q33323235-FE98CAE9-002E-4A51-B66B-28FAD9D2280D Q33560536-14B9B13F-234F-4221-B337-37875E05C494 Q33642003-F0E9D97C-C0C8-407E-AC66-D26898091822 Q34087598-4CA94212-D5F8-4C68-A460-BF2EA460AAA0 Q34333169-77FF97BB-4609-40DF-B7AC-BD873EDBBEBE Q34389508-82C738C8-7473-4752-B8BD-37FCB29B0F21 Q34549009-F42DBD79-4F8C-47AB-8BDF-7EE05823BB2B Q34649993-78D9AA0A-6C75-4219-9220-D3D98CF37653 Q34933977-37D5F189-2551-43B0-946A-F575DAFD68BC Q35338994-F65D6F3B-4201-451F-A2DA-2EEEEE2751A4 Q35556586-DA49D73B-2680-4456-9017-F14DDB2281C2 Q35611698-998AE7D1-0272-445B-B916-06EE957C426A Q36095679-3E4457FF-599C-4FC3-AA31-CD631CC28291 Q36147848-E7EEBE64-51DC-41A7-A97F-7636E2B6D556 Q36179524-5F8D1731-A2B2-4A26-BD83-97F672D4A6F1 Q36793921-AC9636C8-E76E-40A7-AC12-0CBF1ADE5EA9 Q37114841-4F413275-64B5-4D47-8154-6575BC1AA83A Q37407161-718FD8B3-A48F-4212-A3D3-D0A2A813288B Q37633550-DD965C98-E129-4BF9-A77C-6B361BB1ECEA Q37729272-E800599A-42BF-4370-9900-85B467E11442 Q37810120-DBE41C49-B80A-4C9B-9C44-D63317B1DE5C Q38083604-97F0E11D-3062-492C-8DBC-EA544365FF19 Q38101008-49A3C0D2-E36D-409C-9BAE-F2E72271C4D6 Q38780081-18D1BFEE-FDC9-4146-9489-C168C123A509 Q38823622-AFA46658-52C6-46CE-93F0-DAA3B98DEA28 Q39248498-BD3B898E-68C0-4A16-BAFB-AAA3825C60F6 Q39968886-D5117428-CA82-460A-985B-DB3DFBF676B6 Q43121205-315C8E40-B797-4236-B14D-C0F9A8EB369A Q58585823-2A0296C7-1AEA-4989-ACD8-B69965EFFE5B

P2860

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease

http://www.wikidata.org/entity/Q35611709

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Serum proteome profiling detec ...... s markers for advanced disease

@ast

Serum proteome profiling detec ...... s markers for advanced disease

@en

type

label

Serum proteome profiling detec ...... s markers for advanced disease

@ast

Serum proteome profiling detec ...... s markers for advanced disease

@en

prefLabel

Serum proteome profiling detec ...... s markers for advanced disease

@ast

Serum proteome profiling detec ...... s markers for advanced disease

@en

P1433

Q35611709-BEA49F04-1B40-4F8E-A4E8-1B3D656C2077

P1476

Q35611709-B3EF0000-3729-428F-AB1A-12E8F0CA6392

P2093

Q35611709-0818E779-151B-4FD3-9F19-EC575772E63E

Q35611709-12D9953A-247D-4C61-A243-289970925C02

Q35611709-35525023-6A7C-44D7-8CCC-EA8B7A88FBF1

Q35611709-53CEC338-1484-4491-8320-077291064C6D

Q35611709-571027A6-66F8-4E5E-ACC6-24ED38DB5C6C

Q35611709-61EBE48C-E862-4A3F-A287-8BA5CF03D372

Q35611709-665AB5AF-5B20-4E84-8CCD-0420E8A9C3F6

Q35611709-6854EBC9-192A-41C3-AF87-6FD6E5D12BAF

Q35611709-75324A48-3A62-47F9-93C3-B39D37F7F083

Q35611709-758BF0AE-8AC0-4F7D-B23A-E13A9A4C1142

P2860

Q35611709-02DE4C94-75E1-47C8-86F1-480CC59A74EB

Q35611709-16B667D9-A492-444A-8002-C75D49F607DB

Q35611709-1757067D-7975-4758-9DB2-7D033E8C0118

Q35611709-1D652E77-5A52-4C47-B10B-3DB4F057AA36

Q35611709-1DF0ADE0-B021-42C3-9737-48597467C0F7

Q35611709-20C25E69-9244-4341-A585-D5760D5D04C7

Q35611709-245D5A34-F18E-4CC9-A265-E1CC1FDAAF02

Q35611709-25664598-16FF-4D55-9733-E44FFE2C5685

Q35611709-273326D0-664A-4B4D-B1D3-4319C5E314C3

Q35611709-410B4A51-DC2F-4F34-9AAD-E4B42C831596

P304

Q35611709-46753F0C-572B-43C6-9B9B-BE4F06EA6C6C

P31

Q35611709-99C01647-EC9A-43AA-8959-F5015C26F7A3

P356

Q35611709-803A2576-1003-4167-8319-C31F3A5C71CA

P407

Q35611709-BE98DE15-ED43-4E5D-BEAE-9E53C50D3291

P433

Q35611709-0ACBF9A6-9C3F-4C0F-804D-FBD41A0D491F

P478

Q35611709-F8276654-F45C-40BF-AC38-9512B61BE7C9

P50

Q35611709-83BEE594-5E19-4E40-AC77-2DAA24B3113E

Q35611709-877C8A2F-2961-4F4A-80A2-363DD05D45DE

Q35611709-B7E401AE-5366-4ACF-B817-1223BA8B5FA8

P577

Q35611709-C5C26872-BDA1-4DD7-8370-ADE1A51D126B

P5875

Q35611709-582C8101-4F22-4855-994B-2E24B59281D0

P698

Q35611709-A9861656-8512-430D-81F1-CE1B2E1DB780

P932

Q35611709-87F5BB40-2F79-40FA-9F38-846526C763CF

P356

PNAS.0610330104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Serum proteome profiling detec ...... s markers for advanced disease

@en

P2093

Akos Czibere

http://www.w3.org/2001/XMLSchema#string

Christof Iking-Konert

http://www.w3.org/2001/XMLSchema#string

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Dimitrios Spentzos

http://www.w3.org/2001/XMLSchema#string

Eric T Fung

http://www.w3.org/2001/XMLSchema#string

Franck Grall

http://www.w3.org/2001/XMLSchema#string

Giannoula Klement

http://www.w3.org/2001/XMLSchema#string

Gil Alterovitz

http://www.w3.org/2001/XMLSchema#string

Hasan H Otu

http://www.w3.org/2001/XMLSchema#string

Manuel Aivado

http://www.w3.org/2001/XMLSchema#string

P2860

Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases

Gene expression profiling predicts clinical outcome of breast cancer

A gene-expression signature as a predictor of survival in breast cancer

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer

Proposals for the classification of the myelodysplastic syndromes

International scoring system for evaluating prognosis in myelodysplastic syndromes

The 1982 revised criteria for the classification of systemic lupus erythematosus

Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.

Use of proteomic patterns in serum to identify ovarian cancer.

P304

1307-1312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0610330104

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Norbert Gattermann

Aristoteles A N Giagounidis

P577

2007-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6581964

http://www.w3.org/2001/XMLSchema#string

P698

17220270

http://www.w3.org/2001/XMLSchema#string

P932

1783137

http://www.w3.org/2001/XMLSchema#string